These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. Goulet M; Madras BK J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Visanji NP; Gomez-Ramirez J; Johnston TH; Pires D; Voon V; Brotchie JM; Fox SH Mov Disord; 2006 Nov; 21(11):1879-91. PubMed ID: 16960862 [TBL] [Abstract][Full Text] [Related]
4. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa. Kuoppamäki M; Al-Barghouthy G; Jackson M; Smith L; Zeng BY; Quinn N; Jenner P Mov Disord; 2002 Nov; 17(6):1312-7. PubMed ID: 12465074 [TBL] [Abstract][Full Text] [Related]
5. Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP. Chassain C; Eschalier A; Durif F J Neurosci Methods; 2001 Oct; 111(1):9-16. PubMed ID: 11574115 [TBL] [Abstract][Full Text] [Related]
6. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021 [TBL] [Abstract][Full Text] [Related]
8. Measurement of motor disability in MPTP-treated macaques using a telemetry system for estimating circadian motor activity. Barcia C; De Pablos V; Bautista-Hernández V; Sanchez-Bahillo A; Fernández-Barreiro A; Poza M; Herrero MT J Neurosci Methods; 2004 Mar; 134(1):59-64. PubMed ID: 15102503 [TBL] [Abstract][Full Text] [Related]
9. A highly sensitive automated complex running wheel test to detect latent motor deficits in the mouse MPTP model of Parkinson's disease. Liebetanz D; Baier PC; Paulus W; Meuer K; Bähr M; Weishaupt JH Exp Neurol; 2007 May; 205(1):207-13. PubMed ID: 17341420 [TBL] [Abstract][Full Text] [Related]
10. The footfault test as a screening tool in the 6-hydroxydopamine rat model of Parkinson's disease. Silvestrin RB; de Oliveira LF; Batassini C; Oliveira A; e Souza TM J Neurosci Methods; 2009 Mar; 177(2):317-21. PubMed ID: 19026686 [TBL] [Abstract][Full Text] [Related]
11. Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism. Blume SR; Cass DK; Tseng KY Exp Neurol; 2009 Sep; 219(1):208-11. PubMed ID: 19460369 [TBL] [Abstract][Full Text] [Related]
12. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23. Willis GL; Robertson AD Pharmacol Biochem Behav; 2005 Jan; 80(1):9-26. PubMed ID: 15652376 [TBL] [Abstract][Full Text] [Related]
13. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse. Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411 [TBL] [Abstract][Full Text] [Related]
14. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Fox SH; Visanji NP; Johnston TH; Gomez-Ramirez J; Voon V; Brotchie JM Arch Neurol; 2006 Sep; 63(9):1343-4. PubMed ID: 16966523 [No Abstract] [Full Text] [Related]
15. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373 [TBL] [Abstract][Full Text] [Related]
17. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates. Jakowec MW; Petzinger GM Comp Med; 2004 Oct; 54(5):497-513. PubMed ID: 15575363 [TBL] [Abstract][Full Text] [Related]
18. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540 [TBL] [Abstract][Full Text] [Related]
19. The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. Togasaki DM; Hsu A; Samant M; Farzan B; DeLanney LE; Langston JW; Di Monte DA; Quik M J Neurosci Methods; 2005 Jun; 145(1-2):159-66. PubMed ID: 15922034 [TBL] [Abstract][Full Text] [Related]
20. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Samadi P; Grégoire L; Rouillard C; Bédard PJ; Di Paolo T; Lévesque D Ann Neurol; 2006 Feb; 59(2):282-8. PubMed ID: 16437566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]